Mometasonfuroaat Sandoz (Mometasone Furoate)

Mometasone furoate, the active ingredient in Mometasonfuroaat Sandoz, is a corticosteroid presented as a nasal spray for intranasal use. It is indicated for reducing inflammation in the nasal passages of patients with allergic conditions and nasal polyps.

GNH USA supplies Mometasonfuroaat Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mometasone furoate nasal spray is used to treat inflammatory conditions of the nasal mucosa.

- Allergic rhinitis: reduces nasal congestion, sneezing, and itching associated with seasonal or perennial allergies. - Nasal polyps: decreases polyp size and improves nasal airflow after surgical removal. - Non‑allergic rhinitis: alleviates nasal symptoms caused by irritants or vasomotor triggers.

Mometasone furoate nasal spray may cause local and systemic adverse reactions.

Common Side Effects: - Nasal irritation or burning sensation. - Headache. - Epistaxis (nosebleeds). - Throat irritation or dryness. - Altered taste or bitter taste.

Serious or Rare Side Effects: - Nasal septal perforation. - Severe or persistent epistaxis. - Adrenal suppression with prolonged high‑dose use. - Hypersensitivity reactions such as angioedema or anaphylaxis.

Before using Mometasonfuroaat Sandoz, consider the following precautions.

- Prescription use only: follow the prescriber's instructions for frequency and duration. - Recent nasal surgery or trauma: avoid use until the area has healed. - Glaucoma or cataract patients: monitor intra‑ocular pressure regularly. - Potential adrenal suppression: assess risk if used long‑term or at high doses. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Store at room temperature: keep in the original pack, protect from moisture and heat.

Mometasonfuroaat Sandoz may interact with other medicines. Review the following interaction categories.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure. - Concurrent systemic corticosteroids: increased risk of systemic corticosteroid effects.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may modestly raise exposure. - Protease inhibitors such as ritonavir: may affect metabolism. - Antihistamines: no significant interaction but monitor overall symptom control.